An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss

Medicine and Dentistry

• Thiazolidinedione 100%
• Peroxisome Proliferator Activated Receptor Gamma 80%
• Rosiglitazone 80%
• Bone 40%
• Fracture 20%
• Osteoclast 20%
• Osteoclastogenesis 20%
• Transcription Factor 10%
• Complication 10%
• In Vitro 10%
• Combination Therapy 10%
• Disease Predisposition 10%
• Receptor 10%
• Side Effect 10%
• Ligand 10%
• Maturity Onset Diabetes of the Young 10%
• Cell Nucleus Receptor 10%
• Osteolysis 10%
• Adipocyte 10%
• Osteoblast 10%
• Bone Mass 10%
• Skeletal Homeostasis 10%
• Type 2 Diabetes 10%
• Gene 10%
• Diet 10%
• Male 10%
• Cells 10%
• Adult 10%

Biochemistry, Genetics and Molecular Biology

• Rosiglitazone 80%
• Peroxisome Proliferator-Activated Receptor Gamma 80%
• Thiazolidinedione 50%
• Insulin 40%
• Osteoclastogenesis 20%
• Osteoclast 20%
• CD36 20%
• Homeostasis 10%
• Nested Gene 10%
• Transcription Factor 10%
• Osteolysis 10%
• Nuclear Receptor 10%
• Adipocyte 10%
• C57BL 6 Mouse 10%
• Osteoblast 10%
• Mouse 10%
• Bone Mass 10%
• Contrast 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Peroxisome Proliferator Activated Receptor Gamma 80%
• Rosiglitazone 80%
• Insulin 40%
• Fracture 20%
• Receptor 10%
• Complication 10%
• Side Effect 10%
• Ligand 10%
• C57BL 6 Mouse 10%
• Cell Nucleus Receptor 10%
• Non Insulin Dependent Diabetes Mellitus 10%
• Transcription Factor 10%
• Disease Predisposition 10%
• Mouse 10%